Top stories from 2020 for kidney cancer

Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the Kidney Cancer Programme, at the City of Hope Hospital, California talks about the changes in the management of renal cell carcinoma (RCC) over the past decade. He talks about combination treatments such as nivolumab with ipilimumab, which shows the potential for a complete response in […]

read more

2020 top stories in kidney cancer

This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]

read more

Immunotherapy for the treatment of metastatic sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, such as sunitinib and pazopanib. This study […]

read more

First-line treatment of patients with sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, […]

read more

Atexolizumab plus bevacizumab for sarcomatoid kidney cancer

A study published in European Urology in July looks at the treatment of patients with a specific type of kidney cancer where the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). This is called sarcomatoid kidney cancer and patients with […]

read more

Diagnostic biomarkers for rare subtype of kidney cancer

There are more than 10 different subtypes of renal cell carcinoma (RCC), each with important genetic differences that determine how aggressive they are or their response to treatment. Clear cell RCC is the most common subtype, accounting for 75-80% of cases. A team of scientists at the University of Michigan, USA, have discovered the gene […]

read more

Predictive factors for recurrence after complete metastasectomy in metastatic kidney cancer patients

In this retrospective study, published in Science Direct this month, researchers were looking to identify the factors that would help to predict whether the cancer would come back after surgical removal of renal cell carcinoma (RCC) metastases (metastasectomy). Complete metastasectomy is expected to improve the survival of patients with metastatic RCC. However, for many patients […]

read more

Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma

In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]

read more

Atezolizumab and bevacizumab in patients with advanced non-clear cell renal cell carcinoma

Dr Rana McKay from University of California in San Diego, USA and Dr Monty Pal from the City of Hope Medical Centre in California, USA share in a discussion on the study design and results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal […]

read more

Sarcomatoid RCC – molecular features and new opportunities for treatment

Sarcomatoid renal cell carcinoma (RCC) is difficult to treat and has long been associated with a poor prognosis. Also, the biology of sarcomatoid RCC has remained obscure. Scientists have tried to determine the molecular profile of sarcomatoid RCC and investigate different targeted therapies for genes such as TP53, BAP1, cell cycle, and chromatin-remodelling genes. Investigation of […]

read more
Showing 1 to 10 of 20 results
  TOP